吉利德：Trop2 ADC一線治療HR+/HER2-乳腺三期臨牀失敗

醫藥筆記

11/08

▎Armstrong2025年11月7日，吉利德宣佈Trop2 ADC新藥Trodelvy對比化療一線治療內分泌治療後HR+/HER2-乳腺癌的三期臨牀ASCENT-07沒有達到PFS主要終點，關鍵次要終點OS尚未成熟，但觀察到獲益趨勢，研究將繼續進行以評估OS數據。Trodelvy 2024年銷售額為13.15億美元，2025年前三季度銷售額為10.14億美元，在二線三陰乳腺癌市場佔據第一位的...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582862418"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582862418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582862418?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-08 09:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582862418","market":"us","top_or_hot":-1,"title":"吉利德：Trop2 ADC一線治療HR+/HER2-乳腺三期臨牀失敗","media":"醫藥筆記","content":"<div>\n<p>▎Armstrong2025年11月7日，吉利德宣佈Trop2 ADC新藥Trodelvy對比化療一線治療內分泌治療後HR+/HER2-乳腺癌的三期臨牀ASCENT-07沒有達到PFS主要終點，關鍵次要終點OS尚未成熟，但觀察到獲益趨勢，研究將繼續進行以評估OS數據。Trodelvy 2024年銷售額為13.15億美元，2025年前三季度銷售額為10.14億美元，在二線三陰乳腺癌市場佔據第一位的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德：Trop2 ADC一線治療HR+/HER2-乳腺三期臨牀失敗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德：Trop2 ADC一線治療HR+/HER2-乳腺三期臨牀失敗\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">醫藥筆記</strong><span class=\"h-time small\">2025-11-08 09:31</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>▎Armstrong2025年11月7日，吉利德宣佈Trop2 ADC新藥Trodelvy對比化療一線治療內分泌治療後HR+/HER2-乳腺癌的三期臨牀ASCENT-07沒有達到PFS主要終點，關鍵次要終點OS尚未成熟，但觀察到獲益趨勢，研究將繼續進行以評估OS數據。Trodelvy 2024年銷售額為13.15億美元，2025年前三季度銷售額為10.14億美元，在二線三陰乳腺癌市場佔據第一位的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b\">醫藥筆記</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BSNM7G36.USD","symbol_name":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","article_id":"2582862418","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582862418","pubTimestamp":1762565499,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"▎Armstrong2025年11月7日，吉利德宣佈Trop2 ADC新藥Trodelvy對比化療一線治療內分泌治療後HR+/HER2-乳腺癌的三期臨牀ASCENT-07沒有達到PFS主要終點，關鍵次要終點OS尚未成熟，但觀察到獲益趨勢，研究將繼續進行以評估OS數據。Trodelvy一線治療三陰乳腺癌已經遞交上市申請。總結吉利德Trodelvy為全球首款Trop2 ADC，但作為上一代ADC在適應症拓展的道路上充滿曲折，先後在非小細胞肺癌、尿路上皮癌失敗，此次HR+/HER2-乳腺癌又錯失PFS終點，僅守住三陰乳腺癌這一陣地。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","BK4550":"红杉资本持仓","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","BK4578":"CAR-T","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","GILD":"吉利德科学","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4225":"医疗保健房地产信托","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4203":"医疗保健房地产投资信托","ADC":"艾格里房产","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4566":"资本集团","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4583":"猴痘概念","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4532":"文艺复兴科技持仓","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","HR":"医疗保健房地产信托","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4139":"生物科技","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4568":"美国抗疫概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Gilead: Trop2 ADC first-line treatment of HR+/HER2-breast phase III clinical failure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HR":1.5,"ADC":1.5,"GILD":0.9},"content_text":"▎Armstrong2025年11月7日，吉利德宣佈Trop2 ADC新藥Trodelvy對比化療一線治療內分泌治療後HR+/HER2-乳腺癌的三期臨牀ASCENT-07沒有達到PFS主要終點，關鍵次要終點OS尚未成熟，但觀察到獲益趨勢，研究將繼續進行以評估OS數據。Trodelvy 2024年銷售額為13.15億美元，2025年前三季度銷售額為10.14億美元，在二線三陰乳腺癌市場佔據第一位的市場份額。Trodelvy一線治療三陰乳腺癌已經遞交上市申請。Trodelvy為全球首款Trop-2 ADC藥物，採用SN-38作為payload。總結吉利德Trodelvy為全球首款Trop2 ADC，但作為上一代ADC在適應症拓展的道路上充滿曲折，先後在非小細胞肺癌、尿路上皮癌失敗，此次HR+/HER2-乳腺癌又錯失PFS終點，僅守住三陰乳腺癌這一陣地。吉利德圍繞Trodelvy還在探索小細胞肺癌、子宮內膜癌等適應症。相比之下，科倫博泰sac-TMT為全球首款獲批治療肺癌的Trop2 ADC，在適應症擴展的過程中不斷取得臨牀突破，合作伙伴默沙東已開展15項全球三期臨牀。Armstrong技術全梳理系列GPRC5D靶點全梳理；CD40靶點全梳理；CD47靶點全梳理；補體靶向藥物技術全梳理；補體藥物：眼科治療的重要方向；Claudin 6靶點全梳理；Claudin 18.2靶點全梳理；靶點冷暖，行業自知；中國大分子新藥研發格局；被炮轟的「me too」；佐劑百年史；胰島素百年傳奇；CUSBEA：風雨四十載；中國新藥研發的焦慮；中國生物醫藥企業的研發競爭；中國雙抗競爭格局；中國ADC競爭格局；中國雙抗技術全梳理；中國ADC技術全梳理；Ambrx技術全梳理；Vir Biotech技術全梳理；Immune-Onc技術全梳理；亙喜生物技術全梳理；康哲藥業技術全梳理；科濟藥業技術全梳理；愷佧生物技術全梳理；同宜醫藥技術全梳理；百奧賽圖技術全梳理；騰盛博藥技術全梳理；創勝集團技術全梳理；永泰生物技術全梳理；中國抗體技術全梳理；德琪醫藥技術全梳理；德琪醫藥技術全梳理2.0；和鉑醫藥技術全梳理；榮昌生物技術全梳理；再鼎醫藥技術全梳理；藥明生物技術全梳理；恆瑞醫藥技術全梳理；豪森藥業技術全梳理；正大天晴技術全梳理；吉凱基因技術全梳理；基石藥業技術全梳理；百濟神州技術全梳理；百濟神州技術全梳理第2版；信達生物技術全梳理；信達生物技術全梳理第2版；中山康方技術全梳理；復宏漢霖技術全梳理；先聲藥業技術全梳理；君實生物技術全梳理；嘉和生物技術全梳理；志道生物技術全梳理；道爾生物技術全梳理；尚健生物技術全梳理；康寧傑瑞技術全梳理；科望醫藥技術全梳理；岸邁生物技術全梳理；禮進生物技術全梳理；康橋資本技術全梳理；餘國良的抗體藥佈局；荃信生物技術全梳理；安源醫藥技術全梳理；三生國健技術全梳理；仁會生物技術全梳理；樂普生物技術全梳理；同潤生物技術全梳理；宜明昂科技術全梳理；派格生物技術全梳理；邁威生物技術全梳理；Momenta技術全梳理；NGM技術全梳理；普米斯生物技術全梳理；普米斯生物技術全梳理2.0；三葉草生物技術全梳理；貝達藥業抗體藥全梳理；澤璟製藥抗體藥全梳理；恆瑞醫藥抗體藥全梳理；齊魯製藥抗體藥全梳理；石藥集團抗體藥全梳理；豪森藥業抗體藥全梳理；華海藥業抗體藥全梳理；科倫藥業抗體藥全梳理；百奧泰技術全梳理；凡恩世技術全梳理。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}